WeCare
BehavioralThe 7-week WECARE intervention was designed to improve caregiving skills, alleviate caregiver distress, and enhance the psychosocial well-being of dementia caregivers.
NCT Number: NCT07539350
The purpose of this study is to test WECARE, a seven-week multimedia intervention designed to reduce psychosocial distress and provide education and support for caregivers. This study will include Chinese American family caregivers of persons living with Alzheimer's disease and related dementias. Participants will engage with digital learning materials and supportive resources over the course of the program. The goal is to determine whether this approach improves caregiver well-being and reduces stress related to caregiving.
Trial opening soon.
Get Notified21 year–100 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(1) evidence of severe cognitive impairment or mental disorders, or (2) the care recipient was receiving hospice care or had a life expectancy of fewer than six months.
The 7-week WECARE intervention was designed to improve caregiving skills, alleviate caregiver distress, and enhance the psychosocial well-being of dementia caregivers.
Time frame: Baseline, and Follow-Up at Weeks 11-12 (4 to 5 weeks after completion of the intervention)
The baseline and follow-up differences in depressive symptoms will be assessed using the Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D is a 20-item survey instrument designed to measure the frequency and severity of depressive symptoms. The total score is calculated by summing the responses to all 20 items. The total scale ranges from 0 to 60, with higher scores indicating more severe depressive symptoms (a worse outcome). The primary analysis will calculate the difference in this total score between baseline and follow-up.
adults and dementia caregivers.
Time frame: Baseline, and Follow-Up at Weeks 11-12 (4 to 5 weeks after completion of the intervention)
The baseline and follow-up differences in caregiving burden will be assessed using the 12-item Zarit Burden Interview (ZBI-12). The ZBI-12 is designed to measure the subjective physical, psychological, and social burden experienced by caregivers. Each item is rated on a 5-point scale from "never" (0) to "nearly always" (4), The total score is calculated by summing the responses to all 12 items. The total scale ranges from 0 to 48, with higher scores indicating greater caregiving burden (a worse outcome). The primary analysis will calculate the difference in this total score between baseline and follow-up.
Time frame: Baseline, and Follow-Up at Weeks 11-12 (4 to 5 weeks after completion of the intervention)
The baseline and follow-up differences in life satisfaction will be assessed using the Satisfaction with Life Scale (SWLS). The SWLS is a 5-item survey instrument designed to measure a person's global cognitive judgments of satisfaction with their life. The total score is calculated by summing the responses to all 5 items. The total scale ranges from 0 to 30, with higher scores indicating greater life satisfaction (a better outcome). The primary analysis will calculate the difference in this total score between baseline and follow-up.
Time frame: Baseline, and Follow-Up at Weeks 11-12 (4 to 5 weeks after completion of the intervention)
The baseline and follow-up differences in caregiving mastery will be assessed using the Caregiving Mastery Scale. This 7-item survey instrument is designed to measure a caregiver's self-perception of their ability to effectively manage caregiving tasks and challenges. The total score is calculated by summing the responses to all 7 items. The total scale ranges from 0 to 28, with higher scores indicating greater caregiving mastery (a better outcome). The primary analysis will calculate the difference in this total score between baseline and follow-up.
Time frame: Baseline, and Follow-Up at Weeks 11-12 (4 to 5 weeks after completion of the intervention)
The baseline and follow-up differences in care-recipient problem behaviors will be assessed using the Revised Memory and Problem Behavior Checklist (RMBPC). The RMBPC is a 24-item survey instrument designed to measure observable behavioral problems in care recipients across three subdomains: memory-related issues, depressive behaviors, and disruptive behaviors. The total score is calculated by summing the Yes (1) or No (0) responses to all 24 items. The total scale ranges from 0 to 24, with higher scores indicating a higher frequency of problem behaviors (a worse outcome). The primary analysis will calculate the difference in this total score between baseline and follow-up.
Time frame: Baseline, and Follow-Up at Weeks 11-12 (4 to 5 weeks after completion of the intervention)
The baseline and follow-up differences in caregivers' positive aspects of caregiving will be measured by Positive Aspects of Caregiving Scale, a 9-item scale 5-point Likert scale from 0 to 4, with total scores ranging from 0 to 36, with higher score indicating more positive perception of caregiving. The baseline and follow-up differences in the scores will be calculated.
George Mason University
Other
WECARE: A Personalized Intervention for Underserved Chinese American Dementia Caregivers
Acronym: WECARE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738016
Artificial Intelligence, Asthma in Children
Miami, Florida, United States
View Trial DetailsNCT07702864
Adenocarcinoma, Behavior
Tucson, Arizona, United States
View Trial DetailsNCT07594730
ADHD, Attention Deficit Disorder with Hyperactivity
New York, United States
View Trial DetailsNCT07672340
Behavior, Behavioral Symptoms
View Trial Details